Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
MethodImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Several of these immune suppressive cytokines/chemokines induced in PDOTS were also components of the recently reported innate PD-1 resistance (IPRES) gene expression signature (14), which correlated with nonresponse but missed statistical significance (Supplementary Fig.”
BackgroundGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“These designations were adapted from Van Allen and colleagues (12).”
BackgroundSelf-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586 · cited 1×
“S4B and S4C), suggesting the need for alternative strategies that more broadly inhibit immune-suppressive signaling within the TME and reactivate T cells (31, 32).”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559 · cited 1×
“Existing patient-derived cancer models, including circulating tumor cells (CTC), organoid cultures, and patient-derived xenografts (PDX) can guide precision cancer therapy (20, 21), but take weeks to months to generate and lack the native tumor immune microenvironment.”
BackgroundLoss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · cited 1×
“S4A), an immunosuppressive chemokine associated with resistance to PD-1 blockade (30).”
BackgroundCCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · cited 1×
“S8F and S8G) and not in subcutaneously implanted tumors, consistent with a known relationship to lymph-node architecture (36), further highlighting an important distinction of PDOTS models which are derived from autochthonous tumors.”
BackgroundPD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · cited 1×
“Immunophenotyping and Secreted Cytokine Profiling Using Patient-Derived Organotypic Tumor Spheroids We next immunophenotyped a large panel of PDOTS (n = 40) by flow cytometry, enriching for cancers responsive to PD-1 blockade, such as melanoma (4) and Merkel cell carcinoma (35), to establish feasibility of ex vivo PDO…”
BackgroundTumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · cited 1×
“S4B and S4C), suggesting the need for alternative strategies that more broadly inhibit immune-suppressive signaling within the TME and reactivate T cells (31, 32).”
BackgroundIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Self-citationCD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · cited 1×
“Immunophenotyping and Secreted Cytokine Profiling Using Patient-Derived Organotypic Tumor Spheroids We next immunophenotyped a large panel of PDOTS (n = 40) by flow cytometry, enriching for cancers responsive to PD-1 blockade, such as melanoma (4) and Merkel cell carcinoma (35), to establish feasibility of ex vivo PDO…”
BackgroundSelf-citationPitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041 · cited 2×
“Innate resistance to PD-1 blockade remains a major challenge, and strategies to overcome immune suppression and render the TME more permissive to T-cell infiltration and function are under preclinical and clinical evaluation (3, 9, 10).”
BackgroundChen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · cited 1×
“CCL19 is also strongly expressed in lymph-node high endothelial venules (49), and another recent study demonstrated endothelialspecific induction of CCL19 and CXCL13 in cancer-associated endothelial cells following combined antiangiogenic therapy with PD-L1 blockade (50).”
BackgroundDuraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Self-citationObstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702 · cited 1×
“org importance of the tumor microenvironment (TME) in modulating T-cell function, particularly in response to PD-1 blockade (19), more sophisticated tumor models that incorporate features of the TME are needed to elucidate cellular, molecular, and immunologic mechanisms of response and resistance.”
BackgroundEctopic lymphoid-like structures in infection, cancer and autoimmunity
Pitzalis, C., Jones, G. W., Bombardieri, M., & Jones, S. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3700 · Cited by 698 · cited 1×
“Interestingly, both CCL19 and CXCL13 have established roles in lymphoid neogenesis (51).”
BackgroundResistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572 · cited 1×
“Innate resistance to PD-1 blockade remains a major challenge, and strategies to overcome immune suppression and render the TME more permissive to T-cell infiltration and function are under preclinical and clinical evaluation (3, 9, 10).”
BackgroundPrecision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · cited 1×
“Functional assays evaluate drug effects through one or more methods, including dynamic evaluation of target engagement and pathway activation that can be measured rapidly, avoiding the complications inherent in longer-term ex vivo culture (17, 39).”
BackgroundSelf-citationReardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405 · cited 2×
“To examine ex vivo killing in an orthotopic anti–PD-1–sensitive model, we also prepared MDOTS from explanted GL261 glioma tumors (29), which similarly retained sensitivity to ex vivo PD-1 blockade in a CD8+ T cell–dependent manner (Supplementary Fig.”
MethodSelf-citationPD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405 · cited 1×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
MethodFunctional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366 · cited 1×
“Functional assays evaluate drug effects through one or more methods, including dynamic evaluation of target engagement and pathway activation that can be measured rapidly, avoiding the complications inherent in longer-term ex vivo culture (17, 39).”
BackgroundMouse models in oncoimmunology
Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.91 · Cited by 343 · cited 1×
“Novel ex vivo systems that retain key features of the native immune TME and are analyzed in real time may accelerate identification of predictive and/or prognostic biomarkers, facilitate identification of therapies to combat anti–PD-1/ PD-L1 resistance, and drive translational research efforts to ultimately guide opti…”
BackgroundTaube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 246
Deng, R., Bumbaca, D., Pastuskovas, C. V., Boswell, C. A., West, D., Cowan, K. J., Chiu, H., McBride, J., Johnson, C., Xin, Y., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1136043 · Cited by 199
Khaitan, D., Chandna, S., Arya, M., & Dwarakanath, B. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-12 · Cited by 196
Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 192
Self-citationInfluence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids
Mueller-Klieser, W., Freyer, J. P., & Sutherland, R. M. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.58 · Cited by 184 · cited 1×
“For example, previous studies evaluating hypoxia in multicellular tumor spheroids have demonstrated that spheroids measuring <200 μm in size do not exhibit signs of hypoxia, whereas growth to diameters of approximately 200 to 300 μm results in formation of central hypoxic regions in the spheroid core, and in spheroids…”
BackgroundScreening therapeutic EMT blocking agents in a three-dimensional microenvironment
Aref, A. R., Huang, R. Y.-J., Yu, W., Chua, K.-N., Sun, W., Tu, T.-Y., Bai, J., Sim, W.-J., Zervantonakis, I. K., Thiery, J. P., et al. (2013) · Integr. Biol. · doi:10.1039/c2ib20209c · Cited by 183 · cited 2×
“Microfluidic Device Design and Fabrication Microfluidic device design and fabrication were performed as described (23), with modifications of device dimensions to accommodate larger volumes of media.”
MethodSelf-citationOnder, L., Danuser, R., Scandella, E., Firner, S., Chai, Q., Hehlgans, T., Stein, J. V., & Ludewig, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121462 · Cited by 167
Zboralski, D., Hoehlig, K., Eulberg, D., Frömming, A., & Vater, A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0303 · Cited by 166 · cited 1×
“Lastly, these studies relied on cultured or engineered T-cell lines (43) or T cells derived from peripheral blood mononuclear cells (PBMC) from healthy donors that are phenotypically and functionally distinct from tumor-infiltrating T cells with absent or low expression of immune checkpoints (44).”
BackgroundCancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 153
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Lizotte, P. H., Ivanova, E. V., Awad, M. M., Jones, R. E., Keogh, L., Liu, H., Dries, R., Almonte, C., Herter-Sprie, G. S., Santos, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89014 · Cited by 124
Self-citationRegulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation
Yu, J., Zhou, X., Chang, M., Nakaya, M., Chang, J.-H., Xiao, Y., William Lindsey, J., Dorta-Estremera, S., Cao, W., Zal, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7074 · Cited by 118 · cited 17×
“To determine if MDOTS profiling predicted in vivo response to dual TBK1/IKKε inhibition, BALB/c mice bearing CT26 tumors were treated with Cmpd 1 ± anti–PD-L1 (Fig.”
BackgroundInfluentialYu, H., Shahsafaei, A., & Dorfman, D. M. (2008) · American Journal of Clinical Pathology · doi:10.1309/ajcp62wrkerpxdrt · Cited by 104
“In vitro” 3D models of tumor-immune system interaction
Hirt, C., Papadimitropoulos, A., Mele, V., Muraro, M. G., Mengus, C., Iezzi, G., Terracciano, L., Martín, I., & Spagnoli, G. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.003 · Cited by 102 · cited 1×
“Three-dimensional culture of MDOTS/PDOTS may provide a more realistic environment in which to evaluate tumor–immune interactions (40).”
BackgroundXiao, Y., Zou, Q., Xie, X., Liu, T., Li, H. S., Jie, Z., Jin, J., Hu, H., Manyam, G., Zhang, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161524 · Cited by 87 · cited 1×
“Another recent report demonstrated that TBK1 deletion, specifically in dendritic cells, also enhanced responsiveness to ICB therapy (55).”
BackgroundChang, C.-H., Wang, Y., Li, R., Rossi, D. L., Liu, D., Rossi, E. A., Cardillo, T. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3431 · Cited by 86
A novel mechanism for anti‐EGFR antibody action involves chemokine‐mediated leukocyte infiltration
Hoffmann, T. K., Schirlau, K., Sonkoly, E., Brandau, S., Lang, S., Pivarcsi, A., Balz, V., Müller, A., Homey, B., Boelke, E., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24269 · Cited by 63
IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response
Zhang, J., Feng, H., Zhao, J., Feldman, E. R., Chen, S.-Y., Yuan, W., Huang, C., Akbari, O., Tibbetts, S. A., & Feng, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.083 · Cited by 53
Lizotte, P. H., Jones, R. E., Keogh, L., Ivanova, E. V., Liu, H., Awad, M. M., Hammerman, P. S., Gill, R. R., Richards, W. G., Barbie, D. A., et al. (2016) · Scientific Reports · doi:10.1038/srep31745 · Cited by 30 · cited 2×
“For PBMC studies, human PBMCs isolated from healthy donors were cultured for 45 minutes in either plain media (DMEM + 10% FBS + penicillin–streptomycin) or dissociation media (plain media + 100 U/mL collagenase type IV + 50 μg/mL DNase I) and analyzed by flow cytometry for quantification of surface antigen expression,…”
BackgroundMethodSelf-citation
Cited by
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
“For MDOTS experiments, CT26GFP+cells (2x106) were subcutaneously injected into the right flank using a 27 g needle and tumors were harvested 14 days post transplantation.”
InfluentialSelf-citationOrganoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
“Alternatively, custom microfluidic devices with human tumor suspension-derived microspheroids containing immune cells exhibit response to immunotherapeutics, but without tumor-immune specificity (Deng et al., 2018; Jenkins et al., 2018).”
BackgroundMethodA Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Self-citation
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.